The UPMC OPtimizing Treatment and Impact of Monocolonal antIbodieS Through Evaluation for COVID-19 Trial
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Bamlanivimab (Primary) ; Casirivimab/imdevimab (Primary) ; Etesevimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms OPTIMISE-C19
- 24 Apr 2023 Status changed from completed to discontinued because emergency Use Authorizations for monoclonal antibodies were withdrawn.
- 16 Jun 2022 Status changed from recruiting to completed.
- 13 Apr 2022 Planned number of patients changed from 30000 to 60000.